AR080987A1 - Formas cristalinas polimorficas a y d de la sal mesilato de 7-metil-5(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluorometoxibencil)2,3-dihidroisoindol-1-ona,metodo para prepararlas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del dolor y la ansied - Google Patents

Formas cristalinas polimorficas a y d de la sal mesilato de 7-metil-5(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluorometoxibencil)2,3-dihidroisoindol-1-ona,metodo para prepararlas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del dolor y la ansied

Info

Publication number
AR080987A1
AR080987A1 ARP110101484A ARP110101484A AR080987A1 AR 080987 A1 AR080987 A1 AR 080987A1 AR P110101484 A ARP110101484 A AR P110101484A AR P110101484 A ARP110101484 A AR P110101484A AR 080987 A1 AR080987 A1 AR 080987A1
Authority
AR
Argentina
Prior art keywords
oxadiazol
piperazin
methyl
salt
trifluorometoxibencil
Prior art date
Application number
ARP110101484A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR080987A1 publication Critical patent/AR080987A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Reivindicacion 2: La sal mesilato de 7-metil-5-(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluormetoxibencil)-2,3-dihidroisoindoI-1-ona, Polimorfo A, donde los valores d, 2-theta y los recuentos medidos por XRPD son: segun el cuadro (1) : 2-theta/s valor d recuentos (gamma = 1,5418L) 8,0, 11,1, 250; 17,8, 4,98,1932; 18,4, 4,81, 841; 19, 4,55,1471; 21,0, 4,22, 1841. Reivindicacion 3: La sal mesilato de 7-metil-5-(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2(4-trifluormetoxibencil)-2,3-dihidroisoindol-1-ona, Polimorfo A, de acuerdo con la reivindicacion 2, donde los valores d, 2-theta y recuentos adicionales, medidos por XRPD, son como en cuadro (2): 2-theta/s valor d recuentos ( gamma = 1,5418L) 11,8, 7,5, 264; 15,6, 5,7, 465; 17,1, 5,2, 469; 20,4 4,35, 758; 21,3, 4,2 ,471. Reivindicacion 10: La sal mesilato de 7-metil-5-(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluormetoxibencil)-2,3-dihidroisoindol-1-ona, Polimorfo D, donde los valores d, 2-theta y los recuentos, medidos por XRPD, son: 2-theta/°, valor d, recuentos (gamma = 1,5418L) 10,9, 8,1 977; 15,8, 5,6, 766; 17,7, 5,0, 1003; 18,0, 4,93, 1056; 20,2, 4,39, 913. Reivindicacion 11: La sal mesilato de 7-metil-5-(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluormetoxibencil)-2,3-dihidroisoindol-1-ona, Polimorfo D, de acuerdo con la reivindicacion 2, donde los valores d, 2-theta y recuentos adicionales, medidos por XRPD, son: 2-theta/° valor d, recuentos (gamma = 1,5418L) 16,9, 5,2, 637; 11,8, 7,5, 1668; 14,3, 6,2, 1171.
ARP110101484A 2010-04-30 2011-04-28 Formas cristalinas polimorficas a y d de la sal mesilato de 7-metil-5(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluorometoxibencil)2,3-dihidroisoindol-1-ona,metodo para prepararlas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del dolor y la ansied AR080987A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32966210P 2010-04-30 2010-04-30

Publications (1)

Publication Number Publication Date
AR080987A1 true AR080987A1 (es) 2012-05-23

Family

ID=44861775

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101484A AR080987A1 (es) 2010-04-30 2011-04-28 Formas cristalinas polimorficas a y d de la sal mesilato de 7-metil-5(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluorometoxibencil)2,3-dihidroisoindol-1-ona,metodo para prepararlas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del dolor y la ansied

Country Status (15)

Country Link
US (1) US20130237548A1 (es)
EP (1) EP2563782A4 (es)
JP (1) JP2013525427A (es)
KR (1) KR20130094179A (es)
CN (1) CN102858766A (es)
AR (1) AR080987A1 (es)
AU (1) AU2011245737A1 (es)
BR (1) BR112012027628A2 (es)
CA (1) CA2795218A1 (es)
IL (1) IL222601A0 (es)
MX (1) MX2012012447A (es)
RU (1) RU2012144778A (es)
SG (1) SG184449A1 (es)
TW (1) TW201206913A (es)
WO (1) WO2011136723A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
ES2409215T3 (es) 2007-09-14 2013-06-25 Janssen Pharmaceuticals, Inc. 4-fenil-1H-piridin-2-onas 1-3-disustituidas
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
CA2738849C (en) 2008-10-16 2016-06-28 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
ES2401691T3 (es) 2008-11-28 2013-04-23 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
KR200482429Y1 (ko) 2016-02-16 2017-01-23 이순호 막힘 해소장치를 갖는 양변기
GB2621323A (en) 2022-08-03 2024-02-14 Sirgartan Holdings Ltd Treatments for obsessive compulsive disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1716152B1 (en) * 2004-02-18 2008-07-30 AstraZeneca AB Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途
AU2011203993A1 (en) * 2010-01-07 2012-08-02 Astrazeneca Ab Process for making a metabotropic glutamate receptor positive allosteric modulator - 874

Also Published As

Publication number Publication date
WO2011136723A1 (en) 2011-11-03
US20130237548A1 (en) 2013-09-12
KR20130094179A (ko) 2013-08-23
SG184449A1 (en) 2012-11-29
AU2011245737A1 (en) 2012-12-20
EP2563782A1 (en) 2013-03-06
JP2013525427A (ja) 2013-06-20
CN102858766A (zh) 2013-01-02
IL222601A0 (en) 2012-12-31
CA2795218A1 (en) 2011-11-03
TW201206913A (en) 2012-02-16
EP2563782A4 (en) 2013-09-04
RU2012144778A (ru) 2014-06-10
BR112012027628A2 (pt) 2016-08-09
MX2012012447A (es) 2012-11-21

Similar Documents

Publication Publication Date Title
AR080987A1 (es) Formas cristalinas polimorficas a y d de la sal mesilato de 7-metil-5(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluorometoxibencil)2,3-dihidroisoindol-1-ona,metodo para prepararlas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del dolor y la ansied
PH12021550792A1 (en) 2-(morpholin-4-yl)-1,7-naphthyridines
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
AR089554A1 (es) Formas cristalinas de un inhibidor de la dipeptidil peptidasa-iv
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
CR20160035A (es) Inhibidores de bromodominios
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
BR112018009281A2 (pt) composições para tratar atrofia muscular espinhal
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
UY34578A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas q ue los contienen
CO6781507A2 (es) Novedosos derivados heterociclicos
ECSP14013215A (es) Compuestos novedosos
TW201613864A (en) Novel compounds
MX354914B (es) Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
GB201209587D0 (en) Therapeutic compounds
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
EA201600619A1 (ru) Хромен и 1,1а, 2,7в-тетрагидроциклопропа[с]хромен пиридопиразиндионы в качестве модулятора гамма-секретазы
PH12018500378A1 (en) Novel annelated phenoxyacetamides
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
TR201813294T4 (tr) N-aril-2-amino-4-aril-pirimidin makrosi̇kli̇k poli̇eter türevleri̇ ve bunlarin flt3 ve jak i̇nhi̇bi̇törleri̇ olarak kullanimlari.
PH12016501098A1 (en) Polymorphic and amorphous forms of cortisol 17-alpha-benzoate and methods for the preparation and use thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure